- Home
- PCOR vs MRNA Comparison
PCOR vs MRNA Comparison
Compare PCOR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCOR
- MRNA
- Stock Information
- Founded
- PCOR 2003
- MRNA 2010
- Country
- PCOR United States
- MRNA United States
- Employees
- PCOR N/A
- MRNA N/A
- Industry
- PCOR Computer Software: Prepackaged Software
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCOR Technology
- MRNA Health Care
- Exchange
- PCOR Nasdaq
- MRNA Nasdaq
- Market Cap
- PCOR 10.2B
- MRNA 9.8B
- IPO Year
- PCOR 2021
- MRNA 2018
- Fundamental
- Price
- PCOR $71.16
- MRNA $27.38
- Analyst Decision
- PCOR Buy
- MRNA Hold
- Analyst Count
- PCOR 20
- MRNA 17
- Target Price
- PCOR $81.95
- MRNA $42.40
- AVG Volume (30 Days)
- PCOR 1.5M
- MRNA 12.1M
- Earning Date
- PCOR 10-29-2025
- MRNA 11-06-2025
- Dividend Yield
- PCOR N/A
- MRNA N/A
- EPS Growth
- PCOR N/A
- MRNA N/A
- EPS
- PCOR N/A
- MRNA N/A
- Revenue
- PCOR $1,232,484,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PCOR $15.31
- MRNA N/A
- Revenue Next Year
- PCOR $12.73
- MRNA $9.75
- P/E Ratio
- PCOR N/A
- MRNA N/A
- Revenue Growth
- PCOR 16.08
- MRNA N/A
- 52 Week Low
- PCOR $53.71
- MRNA $23.15
- 52 Week High
- PCOR $88.92
- MRNA $60.65
- Technical
- Relative Strength Index (RSI)
- PCOR 50.18
- MRNA 56.40
- Support Level
- PCOR $70.29
- MRNA $23.91
- Resistance Level
- PCOR $74.49
- MRNA $28.99
- Average True Range (ATR)
- PCOR 2.60
- MRNA 1.22
- MACD
- PCOR -0.21
- MRNA 0.38
- Stochastic Oscillator
- PCOR 18.32
- MRNA 67.03
About PCOR Procore Technologies Inc.
Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.